D.E. Shaw & Co’s Alto Neuroscience ANRO Stock Holding History

D.E. Shaw & Co’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-45,343	Closed	-$1.02M	–	5283
2026 Q1	$1.02M	Sell	45,343 -79,452	-64%	-$1.47M	﹤0.01%	3426
2025 Q4	$2.22M	Buy	+124,795	New	+$1.57M	﹤0.01%	2972

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

D.E. Shaw & Co's ANRO Position: Q2 2026 in Review

D.E. Shaw & Co sold out of Alto Neuroscience (ANRO) in Q2 2026, closing a stake of 45,343 shares — an estimated $1.02M sold.

D.E. Shaw & Co first reported a position in ANRO in Q4 2025 and held it in 2 quarters. The position peaked at $2.22M in Q4 2025. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

D.E. Shaw & Co reported no remaining Alto Neuroscience position as of Q2 2026 after selling out during the quarter.
D.E. Shaw & Co sold 45,343 Alto Neuroscience shares in Q2 2026, an estimated $1.02M.
D.E. Shaw & Co first reported a position in Alto Neuroscience in Q4 2025 and held it in 2 quarters.
D.E. Shaw & Co's Alto Neuroscience position peaked at $2.22M in Q4 2025.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.